- Oops!Something went wrong.Please try again later.
GAITHERSBURG, Md., Aug. 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2022 financial results and operational highlights on Monday, August 8, 2022, following the close of U.S. financial markets. Details of the event and replay are as follows:
Conference call details:
August 8, 2022
4:30 p.m. U.S. Eastern Daylight Time (EDT)
(833) 974-2381 (Domestic) or (412) 317-5774 (International)
Available starting at 7:30 p.m. EDT, August 8, 2022 until 11:59 p.m. U.S. EDT, August 15, 2022
(877) 344-7529 (Domestic) or (412) 317-0088 (International)
ir.novavax.com/events, until November 8, 2022
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received authorization from multiple regulatory authorities globally, including the U.S., EC and the WHO. The vaccine is currently under review by multiple regulatory agencies worldwide, including for additional indications and populations such as adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine candidate in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu*, its quadrivalent influenza investigational vaccine candidate, and is also evaluating an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
*NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season.
Alex Delacroix | 240-268-2022
Ali Chartan or Giovanna Chandler | 202-709-5563
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-second-quarter-2022-financial-results-and-operational-highlights-on-august-8-2022-301596821.html
SOURCE Novavax, Inc.